The National Heart, Lung, and Blood Institute (NHLBI) is offering this Small Business Innovation Research (SBIR) Phase IIB grant to accelerate the commercialization of biomedical technologies addressing heart, lung, blood, and sleep disorders. This grant is specifically designed to bridge the funding gap often encountered by small business concerns developing products for small commercial markets, such as those targeting rare diseases or young pediatric populations (aged 0-12 years). It invites applications from small businesses that have previously received SBIR or STTR Phase II awards for promising projects requiring federal regulatory approval. The aim is to support later-stage research and development, advancing products towards regulatory approval and market entry. A key goal is to foster partnerships between awardees and third-party investors or strategic partners, including patient advocacy organizations, to facilitate successful commercialization.
Opportunity ID: 336581
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-23-008 |
| Funding Opportunity Title: | NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.233 — National Center on Sleep Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 17, 2021 |
| Last Updated Date: | Nov 17, 2021 |
| Original Closing Date for Applications: | Feb 28, 2024 |
| Current Closing Date for Applications: | Feb 28, 2024 |
| Archive Date: | Apr 04, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The Small Business Innovation Research (SBIR) Program is an important National Institutes of Health (NIH) funding mechanism used to develop innovative solutions that address public health challenges. A major objective of the SBIR Program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This gap is increased by the barriers associated with technologies under development for small commercial markets, such as those focused on rare diseases or young pediatric populations. This Funding Opportunity Announcement (FOA) invites small businesses to submit SBIR grant applications to support later stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR (Small Business Technology Transfer) Phase II awards that address rare diseases or young pediatric populations (aged 0-12 years and defined in Section IV, part 7), and will require eventual Federal regulatory approval/clearance. The goal of this FOA and the resulting Phase IIB awards is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between small business awardees and third-party investors and/or strategic partners, including patient advocacy organizations. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 336581 Full Announcement-RFA-HL-23-008 -> RFA-HL-23-008-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270944 | Jan 28, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278391 | Nov 14, 2022 | Feb 28, 2024 | View |
Package 1
Mandatory forms
336581 RR_SF424_5_0-5.0.pdf
336581 PHS398_CoverPageSupplement_5_0-5.0.pdf
336581 RR_OtherProjectInfo_1_4-1.4.pdf
336581 PerformanceSite_4_0-4.0.pdf
336581 RR_KeyPersonExpanded_4_0-4.0.pdf
336581 RR_Budget_3_0-3.0.pdf
336581 PHS398_ResearchPlan_4_0-4.0.pdf
336581 SBIR_STTR_Information_3_0-3.0.pdf
336581 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336581 RR_SubawardBudget30_3_0-3.0.pdf
336581 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
336581 RR_SF424_5_0-5.0.pdf
336581 PHS398_CoverPageSupplement_5_0-5.0.pdf
336581 RR_OtherProjectInfo_1_4-1.4.pdf
336581 PerformanceSite_4_0-4.0.pdf
336581 RR_KeyPersonExpanded_4_0-4.0.pdf
336581 RR_Budget_3_0-3.0.pdf
336581 PHS398_ResearchPlan_5_0-5.0.pdf
336581 SBIR_STTR_Information_3_0-3.0.pdf
336581 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336581 RR_SubawardBudget30_3_0-3.0.pdf
336581 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
